6.3 Medications to Avoid and Drug Safety in Heart Failure

Pharmacovigilance and Medication Safety in Heart Failure

Patients with heart failure maintain a precarious neurohormonal and hemodynamic equilibrium. The introduction of common prescription, over-the-counter (OTC), or herbal medications can abruptly disrupt this balance, precipitating acute cardiorenal injury, fluid retention, flash pulmonary edema, lethal dysrhythmias, or cardiogenic shock. Medication reconciliation and proactive pharmacovigilance are core responsibilities of the Certified Heart Failure Nurse (CHFN).

---

Nonsteroidal Anti-inflammatory Drugs (NSAIDs)

Nonsteroidal anti-inflammatory drugs—including non-selective agents (ibuprofen, naproxen, ketorolac, indomethacin, meloxicam) and selective cyclooxygenase-2 inhibitors (celecoxib)—represent one of the most common causes of preventable heart failure decompensation.

                  PROSTAGLANDIN INHIBITION AND RENAL COLLAPSE

                Physiological State in Heart Failure:
                • Decreased Effective Circulating Arterial Volume
                • Elevated Angiotensin II & Endothelin (Constrict Efferent & Afferent)
                • Compensatory Vasodilatory Prostaglandins (PGE2, PGI2)
                  KEEP RENAL AFFERENT ARTERIOLE DILATED to Preserve Glomerular Filtration
                                      │
                                      ▼
                      NSAIDs Inhibit COX-1 and COX-2
                                      │
                                      ▼
         ┌─────────────────────────────────────────────────────────┐
         │ 1. Acute Afferent Arteriolar Vasoconstriction           │
         │    • Plunging intraglomerular hydrostatic pressure      │
         │    • Abrupt drop in GFR & acute prerenal azotemia       │
         │ 2. Blunting of Loop Diuretic Responsiveness             │
         │    • Loop diuretics rely on renal prostaglandins        │
         │    • Markedly attenuated natriuresis & diuresis         │
         │ 3. Severe Sodium & Water Retention                      │
         │    • Retention of 1 to 2 liters of fluid within days    │
         │ 4. Systemic Vasoconstriction & Afterload Spike          │
         │    • Loss of prostacyclin elevates SVR and blood pressure│
         └─────────────────────────────────────────────────────────┘
                                      │
                                      ▼
             DOUBLES RISK OF ACUTE HEART FAILURE HOSPITALIZATION

Clinical Rules for the CHFN

• All systemic NSAIDs (including COX-2 inhibitors) are contraindicated in patients with heart failure.
• Studies demonstrate an approximate two-fold higher risk of heart failure hospitalization in patients taking NSAIDs.
• Safe Analgesic Alternatives: Acetaminophen (paracetamol, maximum 2,000–3,000 mg/day in divided doses) is the preferred first-line agent for mild-to-moderate musculoskeletal pain. For localized osteoarthritis, topical non-systemic therapies (e.g., topical capsaicin, physical therapy, intra-articular corticosteroid injections) are favored.

---

Calcium Channel Blockers: Non-Dihydropyridines vs. Dihydropyridines

Calcium channel blockers (CCBs) inhibit voltage-sensitive L-type calcium channels. However, their cellular selectivity determines whether they are therapeutic or catastrophic in HFrEF.

Non-Dihydropyridines (Diltiazem, Verapamil)

• Mechanism of Harm: Non-dihydropyridines possess potent negative inotropic (suppress myocardial contractility) and negative dromotropic (slow AV nodal conduction) properties.
• Clinical Rule: Diltiazem and verapamil are strictly contraindicated in HFrEF (LVEF ≤40%). In a failing ventricle dependent on adrenergic drive to sustain cardiac output, administering diltiazem or verapamil causes an immediate reduction in stroke volume, elevates ventricular filling pressures, precipitates acute pulmonary edema, and increases mortality.

Dihydropyridines (Amlodipine, Felodipine)

• Hemodynamic Neutrality: Second-generation dihydropyridines are vascular-selective peripheral vasodilators with minimal direct myocardial depression at standard doses.
• Clinical Trial Evidence: The PRAISE trial (amlodipine) and V-HeFT III trial (felodipine) demonstrated that amlodipine and felodipine are hemodynamically neutral in HFrEF—they do not improve survival, but they do not increase mortality or worsen heart failure.
• Clinical Role: Safe to use as adjunct therapies for refractory hypertension or persistent angina when blood pressure remains elevated despite optimal target-dose quadruple GDMT.
• Avoid Short-Acting Agents: Short-acting dihydropyridines (immediate-release nifedipine) must be avoided due to reflex sympathetic surge and precipitous hypotension.

---

Thiazolidinediones (TZDs): Pioglitazone and Rosiglitazone

Thiazolidinediones are oral insulin-sensitizing agents utilized in Type 2 diabetes mellitus.

• Mechanism of Harm: TZDs are agonists of the peroxisome proliferator-activated receptor-gamma (PPAR-γ) transcription factor. In the renal collecting ducts, PPAR-γ activation stimulates the epithelial sodium channel (ENaC) and sodium-potassium ATPase pumps, driving marked renal sodium and fluid reabsorption.
• Clinical Consequence: Induces severe plasma volume expansion, peripheral edema, weight gain, and acute cardiac decompensation.
• Black Box Warning: The FDA issued a black box warning mandating that pioglitazone and rosiglitazone are contraindicated in patients with NYHA Class III or IV heart failure, and their initiation is not recommended in any patient with symptomatic heart failure.

---

Antiarrhythmic Medications: Proarrhythmia and Negative Inotropy

Ventricular and supraventricular arrhythmias are extraordinarily common in heart failure, yet most antiarrhythmic drugs worsen survival.

Class I Antiarrhythmics (Flecainide, Propafenone, Quinidine, Disopyramide)

• Mechanism of Harm: Class I agents block fast inward sodium channels (INa), slowing conduction velocity. In diseased, scarred, or ischemic myocardium, sodium channel blockade slows conduction heterogeneity, creating ideal substrates for lethal re-entrant ventricular tachycardia and ventricular fibrillation.
• The CAST Trial: The landmark Cardiac Arrhythmia Suppression Trial (CAST) demonstrated that suppressing asymptomatic ventricular ectopy with encainide or flecainide post-myocardial infarction produced a nearly threefold increase in arrhythmic death and total mortality.
• Clinical Rule: Class I antiarrhythmics are absolutely contraindicated in patients with structural heart disease and HFrEF.

Dronedarone

• A non-iodinated benzofuran derivative structurally related to amiodarone.
• The ANDROMEDA Trial: Evaluated dronedarone in patients recently hospitalized with symptomatic heart failure and reduced LV function. The trial was terminated prematurely due to a doubling of mortality (predominantly worsening heart failure death) in the dronedarone arm (p = 0.03).
• Clinical Rule: Dronedarone is contraindicated in NYHA class IV heart failure or symptomatic heart failure with recent decompensation, and it is generally avoided in HFrEF.

Safe Antiarrhythmic Options in HFrEF

Only two antiarrhythmic agents have demonstrated neutral mortality (neither improving nor worsening long-term survival) in patients with HFrEF requiring rhythm control:

1. Amiodarone (Class III): Broad electrophysiologic properties (blocks K⁺, Na⁺, Ca²⁺, and adrenergic receptors). Proven safe regarding mortality in trials such as CAMIAT and EMIAT. Requires vigilant surveillance for pulmonary, thyroid, hepatic, and corneal toxicities.
2. Dofetilide (Class III): Pure IKr potassium channel blocker. Evaluated in the DIAMOND-CHF trial; demonstrated neutral all-cause mortality with effective conversion and maintenance of sinus rhythm in atrial fibrillation. Requires mandatory in-hospital telemetric initiation for at least 3 days to monitor for QTc prolongation and torsades de pointes.

---

Over-the-Counter, Herbal, and Nutritional Hazards

Heart failure patients frequently self-administer over-the-counter remedies without recognizing their cardiotoxic and hemodynamic consequences.

               HAZARDOUS OVER-THE-COUNTER & NUTRITIONAL SUBSTANCES

  ┌─────────────────────────┐  ┌─────────────────────────┐  ┌─────────────────────────┐
  │ Sympathomimetic Cold    │  │ Sodium-Loaded           │  │ Licorice Root           │
  │ Decongestants           │  │ Effervescent Formulations│  │ (Glycyrrhizin)          │
  ├─────────────────────────┤  ├─────────────────────────┤  ├─────────────────────────┤
  │ • Pseudoephedrine       │  │ • Alka-Seltzer          │  │ • Natural black licorice│
  │ • Phenylephrine         │  │ • Effervescent aspirin  │  │ • Herbal supplements   │
  │ • Oxymetazoline spray   │  │ • Bromo-Seltzer         │  │ • Chewing tobacco      │
  ├─────────────────────────┤  ├─────────────────────────┤  ├─────────────────────────┤
  │ Mechanism:              │  │ Mechanism:              │  │ Mechanism:              │
  │ Alpha-1 vasoconstriction│  │ Sodium bicarbonate base │  │ Inhibits 11β-HSD2       │
  │ & Beta-1 stimulation    │  │ contains 500-1000 mg Na+│  │ enzyme; cortisol binds  │
  │                         │  │ per dose                │  │ mineralocorticoid rec.  │
  ├─────────────────────────┤  ├─────────────────────────┤  ├─────────────────────────┤
  │ Clinical Hazard:        │  │ Clinical Hazard:        │  │ Clinical Hazard:        │
  │ Acute afterload spike,  │  │ Blatant sabotage of 2g  │  │ Pseudohyperaldosteronism│
  │ hypertensive crisis,    │  │ sodium restriction;     │  │ Severe Na+ retention,   │
  │ ischemia, arrhythmias   │  │ acute pulmonary edema   │  │ hypertension, hypokalemia│
  └─────────────────────────┘  └─────────────────────────┘  └─────────────────────────┘

1. Sympathomimetic Decongestants: Oral agents (pseudoephedrine, phenylephrine) and topical nasal sprays (oxymetazoline). Stimulate alpha-1 receptors to cause peripheral arterial vasoconstriction, producing an abrupt spike in systemic afterload and left ventricular filling pressures. Concurrent beta-1 stimulation triggers sinus tachycardia and arrhythmias. Instruct patients to use non-pharmacologic saline nasal sprays or intranasal corticosteroids.
2. Sodium-Containing Effervescent Formulations: Products such as Alka-Seltzer, effervescent pain relievers, and fizzy antacids use sodium bicarbonate to generate carbonation. A single standard dose can deliver 500 to 1,000 mg of hidden sodium—up to half of the recommended daily 2,000 mg sodium restriction—triggering acute fluid overload.
3. Licorice Root (Glycyrrhizin): True licorice extract contains glycyrrhizic acid, a potent inhibitor of the renal enzyme 11-beta-hydroxysteroid dehydrogenase type 2 (11β-HSD2). Normally, 11β-HSD2 converts active cortisol into inactive cortisone. When inhibited, high circulating cortisol binds unimpeded to mineralocorticoid receptors in the distal nephron, producing apparent mineralocorticoid excess (pseudohyperaldosteronism): severe sodium retention, hypertension, edema, and life-threatening hypokalemia.

---

Managing Hyperkalemia to Maintain GDMT: Novel Potassium Binders

Hyperkalemia (serum K+ >5.0–5.5 mEq/L) is a leading reason clinicians down-titrate or discontinue mortality-reducing RAAS inhibitors (ARNI/ACEi) and MRAs (spironolactone/eplerenone), particularly in patients with concomitant chronic kidney disease (CKD).

Historical vs. Contemporary Approach

• Historical Failure: Stopping life-saving MRAs or ARNIs at the first sign of mild hyperkalemia, thereby forfeiting their profound long-term survival and cardiorenal benefits.
• Contemporary Paradigm: Correct reversible causes (potassium supplements, salt substitutes, NSAIDs), adjust doses per protocol, and consider gastrointestinal potassium binders to support continuation and titration of MRAs and ARNIs (2022 guideline Class 2b).

Novel Potassium Binders: Patiromer and Sodium Zirconium Cyclosilicate (SZC)

[!IMPORTANT] Practice Transformation: When a patient receiving spironolactone and sacubitril/valsartan develops a serum potassium of 5.3 mEq/L, do not reflexively discontinue the MRA or ARNI. Review dietary and supplement potassium, consider an MRA dose reduction or a potassium binder per protocol, recheck potassium within about 1 week, and preserve the patient's quadruple GDMT.

---

Summary Table: High-Risk Medications in Heart Failure

---

Clinical Case Scenario: Over-the-Counter Decompensation

A 66-year-old male with ischemic HFrEF (LVEF 30%) maintained in stable compensated condition on quadruple GDMT (sacubitril/valsartan, metoprolol succinate, spironolactone, and dapagliflozin) presents to the emergency department with acute severe dyspnea, orthopnea, and a 9-pound weight gain over five days.

• History: The patient reports that one week ago he developed a severe flare of bilateral knee osteoarthritis and head cold symptoms. He began self-medicating with over-the-counter naproxen 220 mg twice daily and an effervescent cold remedy containing sodium bicarbonate and phenylephrine four times daily.
• Physical Exam & Diagnostics: BP 168/96 mmHg (baseline was 116/74 mmHg), HR 98 bpm, respiratory rate 28 breaths/min, oxygen saturation 88% on room air. Auscultation reveals prominent bibasilar moist crackles and an S3 gallop; JVP is 8 cm above the sternal angle; 3+ pitting pedal edema is present.
• Laboratory Evaluation: Serum potassium 5.6 mEq/L, BUN 42 mg/dL, creatinine 2.1 mg/dL (baseline was 1.1 mg/dL). Chest X-ray demonstrates cephalization, Kerley B lines, and bilateral alveolar infiltrates.
• Pathophysiologic Deconstruction:
  1. Naproxen inhibited renal prostaglandins, causing afferent arteriolar constriction and neutralizing the effect of his loop diuretic.
  2. Phenylephrine caused alpha-1 vasoconstriction, spiking afterload (BP 168/96 mmHg) against a failing left ventricle.
  3. The effervescent tablets delivered roughly 2,000 mg of hidden sodium daily, driving intravascular fluid retention.
• Nursing Management: Discontinue naproxen and the effervescent cold remedy immediately. Administer intravenous loop diuretics and supplemental oxygen. Because potassium is 5.6 mEq/L and creatinine has nearly doubled, the team temporarily holds spironolactone, treats the potassium (for example, sodium zirconium cyclosilicate 10 g TID), and monitors closely. Once potassium is ≤5.0 mEq/L and renal function recovers, the MRA is reintroduced, with a binder if needed, so that foundational GDMT is preserved.

---

CHFN Exam Traps & Clinical Pearls

[!WARNING] Exam Trap: Do not assume all calcium channel blockers are contraindicated in heart failure! Non-dihydropyridines (diltiazem, verapamil) are strictly contraindicated due to negative inotropy. However, dihydropyridines (amlodipine, felodipine) are hemodynamically neutral and completely safe for refractory hypertension or angina in HFrEF.

[!IMPORTANT] Clinical Pearl: Understand the mechanism of NSAID-induced diuretic resistance. NSAIDs block the synthesis of vasodilatory renal prostaglandins (PGE₂ and PGI₂), constricting the afferent arteriole, plunging GFR, and preventing loop diuretics from reaching their site of action in the thick ascending limb of Henle.

[!TIP] Clinical Pearl: When managing hyperkalemia, remember that patiromer and sodium zirconium cyclosilicate (Lokelma) are "GDMT enablers." In modern practice, hyperkalemia is treated with binders to keep the patient on life-saving MRAs and ARNIs, rather than automatically stopping GDMT.